BerGenBio is focused on developing a pipeline of transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory illnesses.
Note: Bemcentinib is also being studied in Investigator Led Trials in glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma; Tilvestamab, our selective mAb AXL inhibitor, is being studied in a Phase 1b trial.
